Using Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer

Similar documents
An Integrated National Strategy for Breast Cancer Audit. Martin Lee Gill Lawrence

National Cancer Intelligence Network data usage. 17 November 2015 Veronique Poirier Principal Cancer Analyst NCIN

Breast Test Wales Screening Division Public Health Wales

Breast Screening Data Stephen Scott Head of Informatics LCA

COSD & Source of Referral

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2

Cancer Outcomes and Services Dataset: Implications for clinical teams

What do we know about GBM Patient pathways in England?

Future Direction for Cancer Registries

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1

Complete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting

National Breast Cancer Audit next steps. Martin Lee

The National Cancer Dataset Initiative ddd CTYA SSCRG. Di Riley Associate Director for Clinical Outcomes

Informatics in the new NHS : PHE and NCIN 9 months on. Nicky Coombes National Cancer Intelligence Network

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report

Staging Issues: Lung Cancer & Mesothelioma. Mick Peake Clinical Lead, NCIN Chair, Lung SSCRG

Cancer Alliance Data Pack

Stage Data Capture in Ontario

Trust Board of Directors Public. Denise Gale. For Assurance and Information NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE

Guideline for the Diagnosis of Breast Cancer

Unexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience

Understanding lymphoma: the importance of patient data

BREAST CANCER 2010 COMPARATIVE AUDIT REPORT

National Cancer Peer Review Programme

One Palliative Care Annual Report

National Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns

Cancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012

18 Week 92% Open Pathway Recovery Plan and Backlog Clearance

Parity: Innovation in Practice

Hospital Norovirus Outbreak Reporting

Hypoglycaemia in the community

Guidelines for the Management of Bladder Cancer

plasma MATCH Andrew Wardley,

Lung Cancer MCN Work Plan 2017/18

SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT

Protocol for emergency surgical intervention in patients with a brain tumour v3

Integration of hospital based breast cancer data and population based data at the Greater Poland Cancer Centre

Rare Urological Cancers Urological Cancers SSCRG

What are we aiming for?

Quit Rates of New York State Smokers

National Optimal Lung Cancer Pathways. Dr Sadia Anwar Nottingham University Hospitals NHS Trust Clinical Lead for Lung Cancer

National Lung Cancer Audit outlier policy 2017

Cancer Alliance Data Pack

MDT IMPROVEMENT PROJECT. Professor Muntzer Mughal, UCLH

Faster Cancer Treatment: Using a health target as the platform for delivering sustainable system changes

Waiting Times for Suspected and Diagnosed Cancer Patients

to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced

Brighton and Sussex University Hospitals NHS Trust Board of Directors. Mark Smith Chief Operating Officer

NCIN Breast Cancer Workshop 13 March 2014 Hilton Metropole, NEC, Birmingham. Kieran Horgan, Dick Rainsbury, Mark Sibbering, Gill lawrence

Making the Most of Your Cancer Registry

RTT Exception Report

HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE

East London Community Kidney Service

Apples and pears? A comparison of two sources of national lung cancer audit data in England

A Case of Metastatic Lung Adenocarcinoma EGFR ve, ALK +

National Cancer Waiting Times Monitoring Dataset Guidance Version 9.0

Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer

Cancer Waiting Times in NHSScotland

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: December 2015 NORTH OF SCOTLAND PLANNING GROUP

RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY

Insulin Administration Errors in Adult Community Nursing. Hedy Lehman Assistant Director of Professional Standards, Adult Community Nursing

Quality Standards for Diagnosis and Treatment in Breast Units Across Greater Manchester

Kansas EMS Naloxone (Narcan) Administration

Prognosis for metastatic breast cancer to bones

Audit Report. Bladder Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network

Analysis of Meter Reading Validation Tolerances proposed by Project Nexus

NATIONAL BOWEL CANCER AUDIT The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit

Pennine Acute Hospitals NHS Trust. Advancing Quality Results October 2008 to December 2016

The Single Cancer Pathway

National Xpert MTB/RIF Programme

The Greater Manchester Stroke Operational Delivery Network

Epidemiology of Meningiomas in England

Cancer Waiting Times in NHSScotland

Activity Report April 2012 March 2013

Improving Cancer Pathways. Mel Warwick Macmillan Cancer Manager / Lead Nurse Aintree University Hospital NHS Foundation Trust

National Prostate Cancer Audit. Bill Cross June 2015

Wessex Cancer Alliance. Wessex Cancer Strategic Clinical Network

Dementia Content Report May Produced By The NHS Choices Reporting Team

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2017 report Published XX June 2017

National Bowel Cancer Audit

Stereotactic Ablative Radiotherapy for Prostate Cancer

The Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England

National analysis of lung cancer data: overview

Progress Report March 2016

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Winter Holiday Suicide Myth Continues to be Reinforced in Press Annenberg Public Policy Center Study Finds

Improving Value in Chemotherapy

Audit Report. Testicular Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network

Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation

MasDA Mastectomy Decisions Audit 2015

A Step Forward in Cancer Patient Care:

Monitoring Metastatic Breast Cancer with Serum HER-2/neu: Individual Patient Profiles

Head and Neck Cancers Data Quality Report Radiotherapy and Chemotherapy Data

From Analytics to Action

8.0 Take Home Naloxone

Upper GI Cancer Quality Performance Indicators

Colorectal Cancer Quality Performance Indicators

Telehealth Data for Syndromic Surveillance

Transcription:

Using Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer Dr Gill Lawrence, WM KIT, on behalf of Breast SSCRG Cancer Outcomes Conference, Brighton, June 2013 Counting ALL patients with 2 o BC Information on the incidence of secondary (breast) cancer is incomplete: Clinical trials Some breast units have good data 2006 - Breast Cancer Care Established the Secondary Breast Cancer Taskforce Set up the Stand up and be Counted Campaign June 2008 - at the NCIN launch Data on recurrent and metastatic cancers should be collected Via the Cancer Waiting Times data From 1 April 2012, all NHS Trusts should have been recording recurrent and metastatic breast cancer patients NCWTMDS MDT data The WM KIT has been tasked with monitoring the implementation of this recommendation 2 Secondary breast cancer data collection 1

How can we obtain information on 2 o breast cancers? Cancer registration data: population based recording of primary breast cancers Most registries: record information up to 6/12 months after diagnosis With improved completeness of national dataset HES/PAS NCWTMDS SACT RTDS The National Cancer Registration Service (NCRS) should be able to record data on diagnostic and treatment events along the whole cancer pathway, including those for secondary breast cancers West Midlands NCRS: already records this information with no time limit on follow up 3 West Midlands Recurrence Algorithm 4 Recurrence algorithm Secondary breast cancer data collection 2

West Midlands recurrence algorithm The primary treatment pathway for breast cancer may have a long duration Hard to distinguish between recurrence and progression of The first step in automatically calculating recurrence status Does the case have a clearly defined primary treatment pathway? Once the primary treatment pathway length has been calculated Examine the timing of other diagnosis/treatment events Cases without a clearly defined primary treatment pathway Currently sent for manual checking Testing is ongoing to see if more cases can be included in the algorithm 5 Recurrence algorithm Primary treatment pathway Recent development work has amended the algorithm slightly. Rather than adding a 3 or 8 month buffer at the end of the primary treatment pathway in every case, only extend the primary treatment pathway end date if there were further diagnosis/treatment events recorded in this period 6 Recurrence algorithm Secondary breast cancer data collection 3

Recurrence algorithm results 8,633 surgically treated invasive breast cancers diagnosed in 2003-05 had a clearly defined primary treatment pathway Less than 3 months from diagnosis to first surgery No neo-adjuvant treatment No partial dates recorded for primary surgery, radiotherapy & chemotherapy (which would make the primary treatment pathway unclear) The primary diagnosis phase had a clear end point (a gap of a year before any potential recurrence events) 827 of the 8,633 invasive breast cancers had further diagnosis/treatment events after a gap of a year or more after the primary treatment phase Potential recurrence rate 10% [827/8,633] Maximum follow up period = 9.5 years (1 Jan 2003) Minimum follow up period = 6.5 years (31 Dec 2005) The recurrences recorded on the West Midlands cancer registration database, their timing and nature, will be validated using external clinical input and external clinical databases 7 Recurrence algorithm Monitoring Recurrent and Metastatic Breast Cancer Data Collection 8 Recurrence algorithm Secondary breast cancer data collection 4

Monitoring The West Midlands routinely records information on recurrence and metastasis long after a primary diagnosis of cancer WM NCRS receives data WM NCRS does not receive data WM NCRS receives some data Monitor WM THIS PRESENTATION Secondary breast cancer symptoms MDT diagnosis Treatment plan Patient not discussed at MDT Reports (pathology, imaging ) Reports (surgery, chemo ) ENCORE Diagnosis & Treatment plan logged on CWT WM NCRS 9 Recurrence algorithm Methodology Identify patients with secondary breast cancer on WMCIU s cancer registration database Treated or diagnosed in April-June 2012 Match cohort against CWT Does CWT contain records for these patients October 2011-August 2012? If yes, is a diagnosis of secondary breast cancer recorded on NCWTMDS for the period? Any variation between NHS Trusts? Were patients discussed at MDT? Repeat matching for July-September 2012 Reverse matching: secondary found on NCWTMDS but not on WMCIU database 10 Recurrence algorithm Secondary breast cancer data collection 5

Coding on NCWTMDS CWT data item Values Meaning Cancer treatment event type Metastatic site Cancer or Symptomatic Breast Referral Patient Status 3 Treatment for a local recurrence of a primary cancer 4 Treatment for a regional recurrence of cancer 5 Treatment for a distant recurrence of cancer (metastatic ) 6 Treatment for multiple recurrences of cancer (local and/or regional and/or distant) 7 First treatment for metastatic following an unknown primary 8 Second orsubsequent treatment for metastatic following an unknown primary 1 Bone 2 Brain 3 Liver 4 Lung 5 Other metastatic site 6 Multiple metastatic sites 7 Unknown metastatic site 15 Suspected recurrent cancer 16 Diagnosis of recurrent cancer confirmed - first treatment not yet planned 17 Diagnosis of recurrent cancer confirmed - English NHS first treatment planned 18 Diagnosis of recurrent cancer confirmed - no English NHS treatment planned 19 Diagnosis of recurrent cancer confirmed - subsequent treatment not yet planned 20 Diagnosis of recurrent cancer confirmed - subsequent English NHS treatment planned 11 Recurrence algorithm Matching results - regional/distant metastases Q1 78% 271 patients with regional/ distant metastasis on registration dataset 67% Match within period 181 Match found in NCWTMDS: 211 No match in NCWTMDS 60 (22%) Match outside period 30 49% Secondary 94 (35%) No secondary 87 (32%) Secondary 16 (6%) Before period (5months) 24 No Secondary 8 (3%) Secondary 3 (1%) After period (1 month) 6 No secondary 3 (1%) 79% had subsequent treatment recorded 12 Recurrence algorithm Secondary breast cancer data collection 6

Matching results Ascertainment x Timeliness 67% (181/271) of cases registered in April-June 2012 with regional or distant metastases, had an event recorded in the NCWTMDS within the period of interest (March-July 2012) Q2 = 68% (183/271) Ascertainment x Timeliness x Accuracy 52% (94/181) of these cases, NCWTMDS also recorded the presence of secondary Q2 = 50% (92/183) 35% (94/271) of cases registered in April-June 2012 with regional or distant metastases, also had a secondary event recorded on NCWTMDS within period of interest (March-July 2012) Q2 = 35% (92/271) 13 Recurrence algorithm Results for Individual NHS Trusts 14 Recurrence algorithm Secondary breast cancer data collection 7

%cases with regional/dist mets also recorded on NCWTMDS 13/06/2013 Are regional recs/distant mets identified by cancer registry also on NCWTMDS? Quarter 1 Quarter 2 Range = 0%-86% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Not recording any recurrences/distant mets A B C D E F G H I J K L M N O WM NHS Trust Cancer centres providing RT CWT events included if in Jan Nov 2012 15 WM NHS Trust Are regional recs/distant mets identified by cancer registry also on NCWTMDS? Average No. 1 o BC at Trust in Apr-Jun (2010/11/12) No. cases regional/dist mets at registry (Apr- Jun 2012) Cancer centres providing RT % on CWT with 2 o BC Mar-Jul 2012 Q1 Ratio 2 o /1 o registry data Q1 A 151 20 50% 0.13 B 129 32 34% 0.25 C 124 29 34% 0.23 D 120 24 63% 0.20 E 110 17 24% 0.16 F 108 34 0% 0.31 G 82 33 55% 0.40 H 79 13 46% 0.17 I 63 6 50% 0.10 J 62 20 70% 0.32 K 60 6 83% 0.10 L 58 9 56% 0.15 M 56 7 86% 0.13 N 51 2 50% 0.04 O 34 5 40% 0.15 Total 1287 257 43% 0.20 No. cases regional/dist mets at registry (Jul- Sep 2012) % on CWT with 2 o BC Jun-Oct 2012 Q2 Ratio 2 o /1 o registry data Q2 15 40% 0.10 34 24% 0.26 23 43% 0.19 24 58% 0.20 21 24% 0.19 33 0% 0.30 32 69% 0.39 4 25% 0.05 3 67% 0.05 33 76% 0.53 5 60% 0.08 8 25% 0.14 9 11% 0.16 1 0% 0.02 7 57% 0.21 252 41% 0.20 CWT events included if in Jan Nov 2012 Who will chase this Trust? Higher because of RT to recs? 16 Recurrence algorithm Secondary breast cancer data collection 8

%cases with regional/dist mets discussed at MDT 13/06/2013 Are cases with regional/distant mets identified by cancer registry discussed by MDT? Quarter 1 Quarter 2 Q2 generally higher than Q1 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Not discussing any recurrences/ distant mets at MDT? A B C D E F G H I J K L M N O WM NHS Trust Cancer centres providing RT CWT events included if in Jan Nov 2012 17 Recurrence algorithm Reverse matching Q1 2,387 Patients with secondary breast recorded on NCWTMDS in Jan-Mar 2012 West Midlands resident 224 (9%) Not West Midlands resident 2,163 (91%) Not on registration database 1 (0.4%) On registration database: primary 61 (27%) On registration database secondary/ progression 162 (72%) Could be: second primaries palliative care not included in MDT downloads late registrations Will be divided into local, regional, distant mets and progressive 18 Recurrence algorithm Secondary breast cancer data collection 9

Next steps.. Breast MDTs to ensure information on secondary breast cancer is captured on NCWTMDS Who will follow up Trusts with missing data in the West Midlands? How will we know how much information is missing in Trusts in other regions? The NCRS will collect follow up cancer-related data for all cancer patients, without time limit: HES/PAS, NCWTMDS, pathology reports etc The NCRS will identify potential recurrences/secondary breast cancer Either (direct method) because treatment/diagnosis event is flagged as secondary by clinicians and/or NHS Trusts Path report, NCWTMDS etc Or (indirect method) by applying recurrence algorithm to ENCORE Identify where timing of the treatment/ diagnosis event suggests this is not related to a primary Triggers alert for coder to suspect secondary breast cancer 19 Recurrence algorithm Acknowledgments Breast Cancer Care Dora Wheeler NCIN Di Riley, Associate Director, Clinical Outcomes Programme Martin Lee, Chair Breast SSCRG WM KIT Catherine Lagord Jackie Walton Chris Lawrence Jackie Charman 20 Secondary breast cancer data collection 10